Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

The Pharma Marketing Show Europe 2012: event overview

Rebecca Aris provides an overview of day one at the ‘Pharma Marketing Show Europe 2012’ event as pharmaphorum’s marketing excellence month commences. The recent ‘Pharma Marketing Show Europe 2012’ event, held by health network communication in London was aimed at...

Articles

A new look at patient communications in outcomes-driven heal...

Susan Carr addresses the importance of effectively communicating patient self-management techniques in tackling patient adherence and the role that digital can play in this communication. Around the world, healthcare markets are changing rapidly as patients, healthcare providers and payers demand lower costs, higher quality...

Articles

Challenges to personalised medicine

As our personalised medicine theme comes to an end, Duncan McHale, Vice President of Global Exploratory Development at UCB, shares his thoughts on personalised medicine. Duncan McHale has a long history in personalised medicines. He helped to set up the pharmacogenomics programme at Pfizer...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital